Drugmaker Bayer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bayer subsidiary BlueRock has become the first company to report initial success treating Parkinson's disease in humans using an experimental stem cell therapy, the drugmaker said on Wednesday. The hunt for Parkinson's treatments has seen many setbacks over decades. Bayer said that one year into a Phase I trial with 12 volunteers, BlueRock's therapy was shown to be well-tolerated and that transplanted cells grew as intended in patients' brains.

FRANKFURT (Reuters) -Drugmaker Bayer said on Wednesday that initial testing on 12 volunteers showed its experimental stem cell therapy to treat Parkin...

New Delhi, Aug 25: Drugmaker Bayer on Thursday said it has introduced a medication for the treatment of chronic kidney disease associated with diabetes under the brand name Kerendia. The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes. “The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end-stage renal disease or kidney failure. Despite therapy, these patients often progress to kidney […]